Can You Take Vyvanse While Pregnant? The Evidence-Based Answer on Safety, Risks & Alternatives 2026

Can you take Vyvanse while pregnant? Taking Vyvanse during pregnancy is not formally approved, and the FDA advises caution due to limited human data — but the clinical picture is considerably more nuanced than a simple “no”. The most current evidence, including a 2023 Massachusetts General Hospital National Pregnancy Registry study of 40 first-trimester lisdexamfetamine-exposed pregnancies, found no major congenital malformations and an odds ratio of 0.39 for malformations compared to controls — a reassuring, though preliminary, finding. Against this, the evidence identifies three specific small but real risks: gastroschisis (adjusted OR 3.0), preeclampsia (adjusted relative risk 1.29), and preterm birth (adjusted relative risk 1.30) with continued use in the second half of pregnancy. Critically, the University of Sydney’s Australian population-based cohort study found that adverse pregnancy outcomes — including preeclampsia, preterm birth, and caesarean delivery — occurred at elevated rates in women with ADHD even without medication, confirming that ADHD itself, not solely the medication, drives many of these risks. The clinical decision is therefore not “Vyvanse vs. nothing” but “Vyvanse vs. untreated ADHD”— and both carry documented risks that must be weighed together by the patient and her prescriber.

The Regulatory Position: What the FDA Actually Says

Understanding the regulatory status is the starting point for the clinical conversation:

FDA Pregnancy Category: Under the old FDA category system, amphetamines including lisdexamfetamine were classified as Category C — meaning animal reproduction studies showed adverse effects, but adequate well-controlled studies in humans have not been conducted, and potential benefits may warrant use despite potential risks. The FDA has since moved to a more descriptive pregnancy labelling system that replaced letter categories.

Current FDA prescribing label language:The current Vyvanse FDA label states under Pregnancy: “Limited available data are insufficient to inform drug-associated risk for major birth defects and miscarriage. Adverse pregnancy outcomes, including premature delivery and low birth weight, have been reported in infants born to mothers dependent on amphetamines”. The critical qualifier in this language is “dependent on amphetamines” — which refers to substance abuse, not therapeutic ADHD management at prescribed doses.

The National Pregnancy Registry for ADHD Medications:Massachusetts General Hospital operates this ongoing prospective registry specifically to collect controlled data on ADHD medication use in pregnancy. It is actively enrolling women who are pregnant and taking ADHD medications — including Vyvanse — and comparing outcomes to unexposed controls. The registry’s 2023 interim analysis of lisdexamfetamine-exposed pregnancies (n=40) found no major malformations, with OR 0.39 compared to controls — the most methodologically rigorous data specific to Vyvanse in pregnancy currently available.

The Specific Risks: What the Evidence Actually Shows

Major Congenital Malformations: Reassuring Evidence

The most feared outcome — birth defects — has the most reassuring evidence of the specific risks examined:

The 2023 MGH Pregnancy Registry analysis found no major malformations in 40 infants with first-trimester lisdexamfetamine exposure
The odds ratio for any major malformation from any stimulant exposure versus controls was 0.39 (95% CI, 0.09–1.61) — this confidence interval crosses 1.0 (meaning statistical uncertainty remains), but the point estimate is below 1.0, indicating no signal of increased risk
The finding was explicitly described as “preliminary but reassuring that stimulants do not appear to have major teratogenic effects”
A CDC study found a very small increased risk of abdominal wall defects and limb malformations associated with ADHD medication use early in pregnancy, but the study was small and the absolute risk increase was minimal

Importantly contrasting finding for methylphenidate: While Vyvanse/amphetamines do not appear associated with cardiac malformations, a separate 2025 study published in Maternal and Neonatal Outcomes confirmed that methylphenidate (Ritalin) is associated with a small increased risk of cardiac malformations in neonates. This difference between drug classes is clinically relevant — Vyvanse may actually have a better cardiac malformation safety profile than Ritalin in pregnancy.

Gastroschisis: The Most Specific and Quantified Risk

Gastroschisis — a congenital defect in which the baby’s intestines protrude through the abdominal wall — is the birth defect with the most specific evidence of association with amphetamine use in pregnancy:

The American College of Obstetricians and Gynecologists identifies a gastroschisis risk with adjusted OR 3.0 (95% CI, 1.2–7.4) associated with amphetamine use during pregnancy
This is a real and statistically significant elevated risk
However, the absolute risk requires context: Gastroschisis occurs in approximately 1 in 2,000 pregnancies in the general population. An OR of 3.0 means this becomes approximately 3 in 2,000 pregnancies — still a rare outcome, but tripling of a small baseline risk
The data is from amphetamine class broadly; lisdexamfetamine-specific gastroschisis data is not yet available

Preeclampsia: A Documented Small Increased Risk

Preeclampsia — a pregnancy complication characterised by high blood pressure, protein in the urine, and organ damage risk — shows a documented small increased risk with lisdexamfetamine use:

Adjusted relative risk 1.29 (95% CI, 1.11–1.49) for preeclampsia with lisdexamfetamine use
This is a statistically significant finding — the confidence interval does not cross 1.0
A 29% increased relative risk from a baseline of approximately 5–8% preeclampsia in the general population translates to approximately 6.5–10.3% absolute risk with lisdexamfetamine use
Critically, the University of Sydney cohort study found preeclampsia risk was elevated in women with ADHD even in those who stopped medication before pregnancy — suggesting the underlying ADHD physiology contributes to preeclampsia risk independently of the medication

Preterm Birth: Second-Half of Pregnancy Risk

The evidence for preterm birth is specific to continued stimulant use in the second half of pregnancy:

Adjusted relative risk 1.30 (95% CI, 1.10–1.55) for preterm birth with continued stimulant use in the second half of pregnancy
The risk is concentrated in the second half — particularly the third trimester — rather than first trimester
The University of Sydney population-based cohort study found preterm birth rates were elevated in ADHD women regardless of whether they were currently medicated — again suggesting ADHD itself as a contributing factor
A 2026 PubMed population-based registry study found that after adjusting for comorbid mental disorders and smoking, maternal ADHD was not independently associated with preterm birth — suggesting confounders account for much of the observed risk

Neonatal Withdrawal Symptoms

Infants born to mothers taking amphetamines near delivery may experience transient neonatal withdrawal or adaptation syndrome:

Symptoms include: irritability, agitation, poor feeding, excessive crying, disturbed sleep, tremors
These are typically transient and self-limiting with supportive care
The severity correlates with the dose being taken at the time of delivery
Many prescribers recommend tapering the Vyvanse dose in the weeks before the expected due date to minimise neonatal withdrawal severity
The 2026 PubMed case report found neonatal withdrawal symptoms were present but manageable with supportive care in a patient who used lisdexamfetamine throughout pregnancy

The Risk That Is Never Measured: Untreated ADHD in Pregnancy

This is the dimension of the question that most online resources underemphasise — but which clinical guidelines and Australian research specifically highlight as essential to the decision:

The University of Sydney’s landmark 2018 Australian population-based cohort study — the most methodologically rigorous ADHD and pregnancy outcome study conducted in the Australian context — found:

Women with ADHD were 20–30% more likely to have a caesarean delivery
Their babies had a significantly increased rate of needing support to start breathing or admission to a neonatal unit
These elevated rates affected women who were not diagnosed or treated for ADHD until after giving birth — meaning ADHD itself was the predictor, not medication exposure
Lead author Alison Poulton (University of Sydney) specifically stated: “These adverse outcomes were seen even in women not yet treated for ADHD and in women who stopped taking stimulant medication several years before becoming pregnant, suggesting that the increased risk isn’t caused by medication”
Conclusion: “Based on the evidence of this study, the potential benefit of ceasing treatment for ADHD during pregnancy may be limited”

The documented risks of untreated severe ADHD during pregnancy are real and often under-discussed:

Impaired prenatal care adherence — difficulty keeping appointments, following medical advice, managing complex antenatal schedules
Risk-taking behaviour — ADHD is associated with impulsivity and higher rates of substance use, unsafe practices, and poor health self-management
Mental health deterioration — severe untreated ADHD can precipitate or worsen depression, anxiety, and emotional dysregulation, which themselves carry independent risks in pregnancy
Nutritional neglect — difficulty with meal planning and consistent eating, compounded by pregnancy nausea, can impair maternal and fetal nutrition
Postpartum preparation — inability to adequately prepare for infant care due to ADHD-related executive function impairment

The 2026 PubMed case report of lisdexamfetamine use in pregnancy directly compared two pregnancies in the same woman — one unmedicated, one medicated — and found: “The patient experienced significant improvement in her mental well-being compared to her first pregnancy, despite a similar pregnancy course and fetal outcomes”. The fetal outcomes (preterm delivery, NICU admission, cleft palate, micrognathia) were similar in both pregnancies — suggesting the medication neither caused nor prevented these specific outcomes in this patient.

The ACOG Clinical Decision Framework

The American College of Obstetricians and Gynecologists (ACOG) — whose guidance most Australian maternal-fetal medicine specialists reference — provides a structured decision framework for Vyvanse in pregnancy:

When ADHD medication is required for daily functioning:

Continue lisdexamfetamine during pregnancy, as the functional impairment from untreated ADHD can significantly impact the ability to care for oneself and prepare for a child
Counsel patients specifically on the small increased risks of gastroschisis, preeclampsia, and preterm birth
Monitor for signs of preeclampsia throughout pregnancy, particularly in the second half
Arrange monthly growth scans from 20 weeks to ensure adequate fetal growth

When ADHD symptoms are mild or manageable without medication:

Consider non-pharmacological interventions for ADHD during pregnancy
Attempt discontinuation before pregnancy if feasible, with a plan for reinstatement if symptoms become unmanageable
The first trimester (up to 12 weeks) represents the period of highest organogenesis risk — if dose reduction or discontinuation is considered, focusing on this window is most clinically relevant

Trimester-by-Trimester Guidance

The risk profile and clinical approach varies across pregnancy trimesters:

First Trimester (Weeks 1–12): Highest Organogenesis Concern

This is the period of fetal organ development and theoretically the highest vulnerability to teratogenic effects
The gastroschisis risk is an early pregnancy concern
Many prescribers and patients choose to discontinue or reduce Vyvanse during the first trimester specifically and reinstate later
The 2023 registry data provides reassurance that first-trimester exposure to lisdexamfetamine was not associated with major malformations in the study cohort

Second Trimester (Weeks 13–26): Lower Organogenesis Risk

Major organ formation is largely complete — the primary concerns shift from structural malformation to growth and function
Preeclampsia monitoring becomes increasingly relevant
Many patients who discontinued in the first trimester reinstate Vyvanse in the second trimester
Regular blood pressure monitoring is important

Third Trimester (Weeks 27–40): Preterm Birth and Neonatal Withdrawal Risk

The preterm birth adjusted relative risk of 1.30 is specific to second-half-of-pregnancy stimulant use
Neonatal withdrawal severity correlates with dose at time of delivery
Many prescribers recommend gradually reducing the Vyvanse dose in the final 4–6 weeks before expected delivery to minimise neonatal withdrawal
Weekly or bi-weekly growth scans in the third trimester allow early detection of growth restriction

Breastfeeding and Vyvanse: The Post-Delivery Decision

The breastfeeding decision is a separate clinical question that requires its own careful evaluation:

What the evidence shows:

Vyvanse/dextroamphetamine passes into breast milk with a relative infant dose of approximately 2–13.8% of the maternal weight-adjusted dosage
The milk/plasma ratio ranges from 1.9 to 7.5 — meaning breast milk can be more concentrated with the drug than plasma
At a 10 mg maternal dose, infant exposure is in the very low range; at higher therapeutic doses, infant exposure increases proportionally
The DrLact safety database assigns Vyvanse a safety score of 3 out of 8 (“Low Risk”) for breastfeeding, noting “infant levels ranging from undetectable to 14% of maternal plasma levels with no problems observed in clinical follow-up” in dexamphetamine-exposed infants

The FDA label recommendation:The FDA advises against breastfeeding while taking lisdexamfetamine, citing potential serious adverse reactions in nursing infants including cardiovascular effects, growth suppression, and potential neurodevelopmental impacts. This represents a conservative precautionary position.

The 2026 case report finding:The PubMed case report of lisdexamfetamine use in pregnancy and breastfeeding found “one instance of successful breastfeeding with maternal use of lisdexamfetamine with no observed side effects in the infant” at a specific dose. This single case cannot generalise to all doses and circumstances, but provides a documented real-world example.

The clinical decision framework for breastfeeding:

At low doses (10–20 mg) — many clinicians and lactation specialists consider the risk acceptable with infant monitoring
At higher doses (50–70 mg) — the relative infant dose is more clinically significant; the FDA’s caution against breastfeeding is more relevant
Infant monitoring regardless of dose: watch for reduced feeding, irritability, poor weight gain, and unusual sleep patterns
Timing strategy: taking the dose immediately after the first morning feed and pumping/discarding milk at the 3.5-hour peak concentration point (approximately 11:30 AM for an 8 AM dose) reduces infant exposure significantly

Non-Pharmacological ADHD Management During Pregnancy

For women who choose to discontinue or reduce Vyvanse during pregnancy, non-pharmacological ADHD management strategies with evidence bases include:

Cognitive Behavioural Therapy (CBT) for ADHD — the strongest non-pharmacological intervention with documented efficacy for ADHD executive function and emotional dysregulation
Environmental structure and systems — detailed schedules, reminder systems, task-list apps, simplified routines — reducing the executive function load of daily life
Partner and social support systems — actively delegating tasks that require sustained attention or sequential planning
Sleep hygiene — critically important during pregnancy; poor sleep disproportionately worsens ADHD symptoms; consistent sleep schedules and nap management are high-yield
Exercise — moderate aerobic exercise has documented evidence of modest ADHD symptom improvement through dopaminergic mechanisms; particularly appropriate in pregnancy
Dietary modification — limited evidence but widely practised; reducing sugar spikes, ensuring adequate protein, and supporting omega-3 intake may modestly support dopaminergic function
Workplace and academic accommodations — formally requesting accommodations during pregnancy that reduce cognitive demand is an underutilised strategy

Safety and Important Considerations for Australian Patients

The University of Sydney 2018 cohort study is the most geographically relevant research for Australian patients and directly informs the clinical balance — it specifically found that “the potential benefit of ceasing treatment for ADHD during pregnancy may be limited”given that ADHD itself drives many adverse pregnancy outcomes
The 2026 PubMed case report specifically examined lisdexamfetamine in pregnancy and breastfeeding and concluded the patient experienced “significant improvement in mental well-being” during the medicated pregnancy compared to the unmedicated one, with comparable fetal outcomes
RANZCOG guidance (Royal Australian and New Zealand College of Obstetricians and Gynaecologists) recommends individual risk-benefit assessment rather than categorical discontinuation for women requiring ADHD medication in pregnancy — consistent with ACOG’s framework
Both Vyvanse and dexamphetamine are Schedule 8 — pregnant women in Australia requiring stimulant ADHD medication should discuss prescribing authority with their treating specialist, as GP prescribing of Schedule 8 stimulants in pregnancy may require additional consultation with a psychiatrist or maternal-fetal medicine specialist
Do not abruptly stop Vyvanse without medical supervision — sudden discontinuation can cause withdrawal symptoms (fatigue, depression, irritability, hypersomnia) that are themselves harmful to maternal wellbeing and potentially to pregnancy outcomes

Common Misconceptions About Vyvanse in Pregnancy

Myth 1: “Vyvanse causes birth defects.”The most current specific evidence — the 2023 MGH Pregnancy Registry analysis of first-trimester lisdexamfetamine exposure — found no major malformations in 40 exposed infants. The odds ratio of 0.39 compared to controls is reassuring, though preliminary. The birth defects historically attributed to amphetamines in pregnancy primarily come from studies of amphetamine abuse at supratherapeutic doses — not therapeutic ADHD medication use. The FDA language about adverse outcomes in infants “born to mothers dependent on amphetamines” specifically refers to substance abuse, not prescribed ADHD treatment.

Myth 2: “Stopping Vyvanse is always the safe choice.”Stopping Vyvanse eliminates medication-related risks — but leaves ADHD untreated, which carries its own documented risks. The University of Sydney study specifically found that adverse pregnancy outcomes (preeclampsia, preterm birth, caesarean delivery, neonatal unit admission) were elevated in ADHD women regardless of medication status — including in women who had stopped medication years before pregnancy. The decision is therefore not simply “medication = risk; no medication = safe” but a more complex risk-on-both-sides calculation.

Myth 3: “Vyvanse is safer in pregnancy than Ritalin because Ritalin causes heart defects.”This is close to true but requires nuance. A 2025 study confirmed methylphenidate is associated with a small increased risk of neonatal cardiac malformations; amphetamines (including Vyvanse) do not appear to carry this cardiac malformation risk. However, Vyvanse carries specific risks of gastroschisis and preeclampsia that methylphenidate data does not consistently show. Neither medication is categorically “safer” — they have different specific risk profiles.

Myth 4: “You must stop Vyvanse as soon as you find out you’re pregnant.”Abrupt cessation is not required and may not be advisable. The ACOG framework specifically states that continuing lisdexamfetamine is appropriate when ADHD medication is required for daily functioning. The decision involves a collaborative risk-benefit discussion between the patient and her obstetric and psychiatric team — not an automatic stop-all-medication response.

Can you take Vyvanse while pregnant Hobart
Can you take Vyvanse while pregnant Devonport
Can you take Vyvanse while pregnant Launceston
Can you take Vyvanse while pregnant Tasmania
Can you take Vyvanse while pregnant Victoria
Can you take Vyvanse while pregnant Queensland
Can you take Vyvanse while pregnant Canberra
Can you take Vyvanse while pregnant Australian Capital Territory
Can you take Vyvanse while pregnant South Australia
Can you take Vyvanse while pregnant New South Wales
Can you take Vyvanse while pregnant Darwin
Can you take Vyvanse while pregnant Ghan
Can you take Vyvanse while pregnant Northern Territory
Can you take Vyvanse while pregnant Australia
Can you take Vyvanse while pregnant Austria
Can you take Vyvanse while pregnant Germany
Can you take Vyvanse while pregnant United Kingdom
Can you take Vyvanse while pregnant Sweden
Can you take Vyvanse while pregnant Denmark
Can you take Vyvanse while pregnant Norway
Can you take Vyvanse while pregnant Finland
Can you take Vyvanse while pregnant Iceland
Can you take Vyvanse while pregnant Netherlands
Can you take Vyvanse while pregnant Spain
Can you take Vyvanse while pregnant Ireland
Can you take Vyvanse while pregnant Switzerland

FAQ: People Also Ask About Vyvanse in Pregnancy

Can you take Vyvanse while pregnant?There is no absolute contraindication — but it is not recommended without specific clinical justification. The FDA advises caution due to limited human data; the ACOG guidance explicitly supports continuing lisdexamfetamine in pregnancy when it is required for daily functioning, with counselling about small increased risks of gastroschisis, preeclampsia, and preterm birth. The decision should be made in partnership with both the prescribing psychiatrist and the obstetrician, with active monitoring throughout pregnancy.

What are the risks of taking Vyvanse during pregnancy?The four documented specific risks are: gastroschisis (adjusted OR 3.0, though absolute risk remains small), preeclampsia (adjusted RR 1.29), preterm birth with second-half-of-pregnancy use (adjusted RR 1.30), and neonatal withdrawal symptoms in infants delivered while the mother is taking the medication. Reassuringly, major congenital malformations — the most feared outcome — have not been observed in the most current lisdexamfetamine-specific registry data.

What happens if you take Vyvanse in the first trimester?The 2023 MGH Pregnancy Registry data found no major malformations in 40 infants exposed to lisdexamfetamine specifically during the first trimester, with an odds ratio of 0.39 compared to controls. This is preliminary but reassuring. The first trimester represents the period of peak organogenesis risk, and many clinicians recommend the most conservative approach during this window — including dose reduction or temporary discontinuation — while acknowledging that the specific Vyvanse data available is not alarming.

Should I stop Vyvanse if I’m trying to get pregnant?This is one of the most important conversations to have with your prescriber before attempting conception — not after. Options include: stopping Vyvanse before conception and assessing whether non-pharmacological management is sufficient; continuing through conception and first trimester with close monitoring; or developing a structured plan for how to manage ADHD at each stage of pregnancy. The University of Sydney evidence supports that stopping medication may not eliminate pregnancy risk, as ADHD itself is associated with adverse outcomes.

Can you breastfeed while taking Vyvanse?The FDA label advises against breastfeeding while taking lisdexamfetamine. Vyvanse passes into breast milk at a relative infant dose of approximately 2–13.8% of the maternal weight-adjusted dose, concentrated approximately 3 times more in milk than in plasma. At low doses (10–20 mg), many lactation specialists consider this manageable with infant monitoring. At higher therapeutic doses, the FDA’s caution is more relevant. A 2026 case report documented successful breastfeeding without observed infant side effects in one patient at a specific dose. This remains an individualised clinical decision requiring prescriber guidance.

Is Vyvanse safer in pregnancy than Adderall?Both are amphetamine-class medications — Vyvanse converts entirely to dextroamphetamine, while Adderall contains mixed amphetamine salts (75% dextroamphetamine, 25% levoamphetamine). The pregnancy risk data is largely based on the amphetamine class broadly, with limited medication-specific differentiation. Since Adderall is not available in Australia, the relevant Australian comparison is Vyvanse versus dexamphetamine — both producing dextroamphetamine, with comparable pregnancy risk profiles.

Disclaimer: This article provides evidence-based clinical information for educational purposes. It does not constitute medical advice. Decisions about ADHD medication use during pregnancy must be made in consultation with a qualified obstetrician and prescribing psychiatrist who can assess individual circumstances, risk factors, and treatment needs.